Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi: ivonescimab or placebo plus pemetrexed and carboplatin after EGFR-TKI failure in EGFR-mutant non-squamous NSCLC
2023-504434-22-00Phase 3Authorised
- Sponsor
- Summit Therapeutics
- Start
- Oct 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ivonescimab + pemetrexed + carboplatin with Placebo + pemetrexed + carboplatin (2 arms). Primary endpoints: Overall survival and Progression-free survival. Planned start Oct 2023; status: authorised.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504434-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504434-22-00.